The role of Alzheimer's disease risk genes in endolysosomal pathways
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
There is ample pathological and biological evidence for endo-lysosomal dysfunction in Alzheimer's disease (AD) and emerging genetic studies repeatedly implicate endo-lysosomal genes as associated with increased AD risk. The endo-lysosomal network (ELN) is essential for all cell types of the central nervous system (CNS), yet each unique cell type utilizes cellular trafficking differently (see Fig. 1). Challenges ahead involve defining the role of AD associated genes in the functionality of the endo-lysosomal network (ELN) and understanding how this impacts the cellular dysfunction that occurs in AD. This is critical to the development of new therapeutics that will impact, and potentially reverse, early disease phenotypes. Here we review some early evidence of ELN dysfunction in AD pathogenesis and discuss the role of selected AD-associated risk genes in this pathway. In particular, we review genes that have been replicated in multiple genome-wide association studies(Andrews et al., 2020; Jansen et al., 2019; Kunkle et al., 2019; Lambert et al., 2013; Marioni et al., 2018) and reviewed in(Andrews et al., 2020) that have defined roles in the endo-lysosomal network. These genes include SORL1, an AD risk gene harboring both rare and common variants associated with AD risk and a role in trafficking cargo, including APP, through the ELN; BIN1, a regulator of clathrin-mediated endocytosis whose expression correlates with Tau pathology; CD2AP, an AD risk gene with roles in endosome morphology and recycling; PICALM, a clathrin-binding protein that mediates trafficking between the trans-Golgi network and endosomes; and Ephrin Receptors, a family of receptor tyrosine kinases with AD associations and interactions with other AD risk genes. Finally, we will discuss how human cellular models can elucidate cell-type specific differences in ELN dysfunction in AD and aid in therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · cited 1×
“Clinically, AD is characterized by progressive memory decline, language and speech defects, impairment of executive function and a progressive impairment of the execution of routine daily activities(Cappa, 2018; Graham et al., 2017; Masters et al., 2015; Querfurth and LaFerla, 2010; Scheltens et al., 2016).”
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 9×
“BIN1 is repeatedly associated with increased AD risk in multiple genomewide studies with an association second after APOE (Harold et al., 2009; Kunkle et al., 2019; Lambert et al., 2013; Seshadri et al., 2010).”
InfluentialRab proteins as membrane organizers
Zerial, M., & McBride, H. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052055 · Cited by 3,381 · cited 1×
“EEs are marked by the GTP-binding protein Rab5 and/or its effector protein, early endosome antigen 1 (EEA1)(Behnia and Munro, 2005; Zerial and McBride, 2001).”
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“GWAS first associated PICALM with AD in 2009(Harold et al., 2009) and this association has been replicated in several studies(Cor-”
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125 · cited 1×
“In addition, one of these genes, SORL1, harbors rare coding variants that may be causal for AD(Scheltens et al., 2021).”
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
Current knowledge on exosome biogenesis and release
Hessvik, N. P., & Llorente, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2595-9 · Cited by 2,362 · cited 1×
“somes have an endosomal origin formed from multivesicular endosomes or multivesicular bodies (MVBs) with several intra-luminal vesicles (ILVs)(Hessvik and Llorente, 2018; van Niel et al., 2018).”
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 14×
“Although not associated with AD by GWAS, EphA4 receptor levels were shown to be decreased in the hippocampus of patients with AD(Simon et al., 2009).”
InfluentialMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 2×
“The genetic details and implications of GWAS to AD have been extensively reviewed and many of these reviews provide a broad overview of these biological pathways(Andrews et al., 2020; Karch and Goate, 2015; Pimenova et al., 2018).”
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212 · cited 1×
“…alter autophagy, and also result in enlarged EEs(Bhalla et al., 2012; Das et al., 2016; Fedeli et al., 2019; Hung and Livesey, 2018; Kwart et al., 2019; La Rosa et al., 2015; Lee et al., 2010; Mecozzi et al., 2014; Nixon, 2017; Reddy et al., 2016; Sannerud et al., 2016; Zhang et al., 2012).”
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 1×
“In 2007, a candidate gene study implicated two haplotypes in SORL1 that were associated with increased AD risk in several population groups (Rogaeva et al., 2007), indicating that SORL1 might be considered an AD risk gene.”
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · cited 1×
“APP is trafficked throughout the ELN and its processing by β and γ secretases occurs in various ELN compartment (Haass et al., 2012; Thinakaran and Koo, 2008) and reviewed in (Winckler et al., 2018).”
Cargo recognition and degradation by selective autophagy
Gatica, D., Lahiri, V., & Klionsky, D. J. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0037-z · Cited by 1,067
A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk
Yang, A. C., Vest, R. T., Kern, F., Lee, D. P., Agam, M., Maat, C. A., Losada, P. M., Chen, M. B., Schaum, N., Khoury, N., et al. (2022) · Nature · doi:10.1038/s41586-021-04369-3 · Cited by 797
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Identification of the Switch in Early-to-Late Endosome Transition
Poteryaev, D., Datta, S., Ackema, K., Zerial, M., & Spang, A. (2010) · Cell · doi:10.1016/j.cell.2010.03.011 · Cited by 752 · cited 3×
“After rapid sorting at the EE, cargo is either directed to late endosomes (LEs) and lysosomes(Luzio et al., 2007; Poteryaev et al., 2010) for degradation or recycled back to the plasma membrane(Maxfield and McGraw, 2004).”
InfluentialClathrin: a unique protein associated with intracellular transfer of membrane by coated vesicles.
Pearse, B. M. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.4.1255 · Cited by 683 · cited 1×
“Clathrin forms a complex lattice like structure around vesicles formed by membrane invaginations(Marsh and McMahon, 1999; Merrifield et al., 2005; Pearse, 1976; Ungewickell and Hinrichsen, 2007).”
Andersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655
Endocytosis unplugged: Multiple ways to enter the cell
Kumari, S., MG, S., & Mayor, S. (2010) · Cell Research · doi:10.1038/cr.2010.19 · Cited by 599
GWAS on family history of Alzheimer’s disease
Marioni, R. E., Harris, S. E., Zhang, Q., McRae, A. F., Hagenaars, S. P., Hill, W. D., Davies, G., Ritchie, C. W., Gale, C. R., Starr, J. M., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0150-6 · Cited by 564
Schwartzentruber, J., Cooper, S., Liu, J. Z., Barrio-Hernandez, I., Bello, E., Kumasaka, N., Young, A. M. H., Franklin, R. J. M., Johnson, T., Estrada, K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00776-w · Cited by 532 · cited 1×
“genetic risk for disease development, including the genes we discuss below (Bellenguez, 2020; Gao et al., 2018; Karch and Goate, 2015; Schwartzentruber et al., 2021; Van Acker et al., 2019).”
Clathrin-independent pathways of endocytosis
Mayor, S., Parton, R. G., & Donaldson, J. G. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016758 · Cited by 525
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506 · cited 1×
“Clinically, AD is characterized by progressive memory decline, language and speech defects, impairment of executive function and a progressive impairment of the execution of routine daily activities(Cappa, 2018; Graham et al., 2017; Masters et al., 2015; Querfurth and LaFerla, 2010; Scheltens et al., 2016).”
Merrifield, C. J., Perrais, D., & Zenisek, D. (2005) · Cell · doi:10.1016/j.cell.2005.03.015 · Cited by 476 · cited 1×
“Clathrin forms a complex lattice like structure around vesicles formed by membrane invaginations(Marsh and McMahon, 1999; Merrifield et al., 2005; Pearse, 1976; Ungewickell and Hinrichsen, 2007).”
Modeling Alzheimer’s disease with iPSC-derived brain cells
Penney, J., Ralvenius, W. T., & Tsai, L.-H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0468-3 · Cited by 471
Nixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400 · cited 14×
“Conversion of EEs to downstream endosomal compartments in the ELN occurs through endosomal maturation that involves a gradual acidification of the lumen(Huotari and Helenius, 2011).”
InfluentialCataldo, A. M., Barnett, J. L., Pieroni, C., & Nixon, R. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-16-06142.1997 · Cited by 393 · cited 1×
“Elegant work in the late 1990s and early 2000s demonstrated that enlarged EEs preceded canonical AD pathology in patient brains, indicating that ELN dysfunction occurs early in the course of disease(Cataldo et al., 1997; Cataldo et al., 2004; Cataldo et al., 2000).”
BIN1 is a novel MYC–interacting protein with features of a tumour suppressor
Sakamuro, D., Elliott, K. J., Wechsler-Reya, R., & Prendergast, G. C. (1996) · Nature Genetics · doi:10.1038/ng0996-69 · Cited by 387 · cited 1×
“BIN1 (Bridging Integrator-1) was originally characterized as a mycinteracting protein, structurally related to amphiphysin(Sakamuro et al., 1996).”
Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363
The biogenesis of lysosomes and lysosome-related organelles
Luzio, J. P., Hackmann, Y., Dieckmann, N. M. G., & Griffiths, G. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016840 · Cited by 330 · cited 1×
“For more in-depth reviews of the ELN we refer to excellent reviews(Gautreau et al., 2014; Hu et al., 2015; Hyttinen et al., 2013; Inpanathan and Botelho, 2019; Klumperman and Raposo, 2014; Kumari et al., 2010; Luzio et al., 2014).”
Expression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains
Karch, C. M., Jeng, A. T., Nowotny, P., Cady, J., Cruchaga, C., & Goate, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050976 · Cited by 328 · cited 1×
“Targeted, quantitative RT-PCR studies using RNA isolated from postmortem brain tissue demonstrated that levels of BIN1 expression are associated with AD progression and age of onset, while expression of neuronal isoforms of BIN1 were associated with duration of the disease (Karch et al., 2012).”
Tebar, F., Bohlander, S. K., & Sorkin, A. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2687 · Cited by 320
Loss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316 · cited 1×
“studies described loss of SORLA expression in neurons in SAD brains (Dodson et al., 2006; Scherzer et al., 2004).”
Interpretation of risk loci from genome-wide association studies of Alzheimer's disease
Andrews, S. J., Fulton-Howard, B., & Goate, A. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30435-1 · Cited by 314 · cited 3×
“The genetic details and implications of GWAS to AD have been extensively reviewed and many of these reviews provide a broad overview of these biological pathways(Andrews et al., 2020; Karch and Goate, 2015; Pimenova et al., 2018).”
Dreyling, M. H., Martinez-Climent, J. A., Zheng, M., Mao, J., Rowley, J. D., & Bohlander, S. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4804 · Cited by 310
Pottier, C., Hannequin, D., Coutant, S., Rovelet-Lecrux, A., Wallon, D., Rousseau, S., Legallic, S., Paquet, C., Bombois, S., Pariente, J., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.15 · Cited by 305
Loss of Bin1 Promotes the Propagation of Tau Pathology
Calafate, S., Flavin, W., Verstreken, P., & Moechars, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.063 · Cited by 265
Jacobsen, L., Madsen, P., Moestrup, S. K., Lund, A. H., Tommerup, N., Nykjær, A., Sottrup-Jensen, L., Gliemann, J., & Petersen, C. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31379 · Cited by 253
Bis, J. C., Jian, X., Kunkle, B. W., Chen, Y., Hamilton-Nelson, K. L., Bush, W. S., Salerno, W. J., Lancour, D., Ma, Y., Renton, A. E., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0112-7 · Cited by 248 · cited 1×
“Genome-wide association studies (GWAS) have identified dozens of loci associated with increased disease risk for developing AD(Bis et al., 2020; Gao et al., 2018; Jansen et al., 2019; Kunkle et al., 2019; Lambert et al., 2013; Marioni et al., 2018).”
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237 · cited 1×
“, 2009) and this association has been replicated in several studies(Corneveaux et al., 2010; Jun et al., 2010).”
Untangling Genetic Risk for Alzheimer’s Disease
Pimenova, A. A., Raj, T., & Goate, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.014 · Cited by 223 · cited 2×
“These studies strongly point to aberrations in the endolysosomal pathway, immune response, and lipid processing as contributing to AD risk(Pimenova et al., 2018).”
Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors
Van Acker, Z. P., Bretou, M., & Annaert, W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0323-7 · Cited by 222 · cited 1×
“Scission of these clathrin coated pits from the plasma membrane is caused by a large GTPase, dynamin(van der Bliek et al., 1993) along with dynamin partners including Bin, amphiphysin and Rvs (BAR) domain proteins, including BIN1(Daumke et al., 2014; McPherson et al., 2013; Takei et al., 1999).”
Novikova, G., Kapoor, M., TCW, J., Abud, E. M., Efthymiou, A. G., Chen, S. X., Cheng, H., Fullard, J. F., Bendl, J., Liu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21823-y · Cited by 214 · cited 1×
“, 2021)as well as AD risk enhancers that may regulate cell-type specific expression(Novikova et al., 2021).”
Miller, S. E., Mathiasen, S., Bright, N. A., Pierre, F., Kelly, B. T., Kladt, N., Schauss, A., Merrifield, C. J., Stamou, D., Höning, S., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.03.002 · Cited by 207 · cited 2×
“, 2014) and Phosphatidylinositol Binding Clathrin Assembly Protein (PICALM) is a monomeric adaptor protein that recruits clathrin to the cell membrane(Meyerholz et al., 2005; Miller et al., 2015).”
Miyashita, A., Koike, A., Jun, G., Wang, L.-S., Takahashi, S., Matsubara, E., Kawarabayashi, T., Shoji, M., Tomita, N., Arai, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058618 · Cited by 196
Amphiphysin 2 (BIN1) in physiology and diseases
Prokic, I., Cowling, B. S., & Laporte, J. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1138-1 · Cited by 188
BIN1 favors the spreading of Tau via extracellular vesicles
Crotti, A., Sait, H. R., McAvoy, K. M., Estrada, K., Ergun, A., Szak, S., Marsh, G., Jandreski, L., Peterson, M., Reynolds, T. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45676-0 · Cited by 171 · cited 1×
“, showed that AD-associated SNPs in BIN1 may promote increased BIN1 expression in microglia and that this, in turn, may affect expression of chaperones that participate in Tau clearance as well as increased release of tau in extracellular vesicles (Crotti et al., 2019).”
Bin1 and CD2AP polarise the endocytic generation of beta‐amyloid
Ubelmann, F., Burrinha, T., Salavessa, L., Gomes, R., Ferreira, C., Moreno, N., & Guimas Almeida, C. (2017) · The EMBO Reports · doi:10.15252/embr.201642738 · Cited by 165
Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
De Rossi, P., Buggia-Prévot, V., Clayton, B. L. L., Vasquez, J. B., van Sanford, C., Andrew, R. J., Lesnick, R., Botté, A., Deyts, C., Salem, S., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0124-1 · Cited by 151
Holler, C. J., Davis, P. R., Beckett, T. L., Platt, T. L., Webb, R. L., Head, E., & Murphy, M. P. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-132450 · Cited by 145 · cited 2×
“neuronal isoforms of BIN1 decreased in AD(Holler et al., 2014).”
Whole‐exome sequencing in 20,197 persons for rare variants in Alzheimer's disease
Raghavan, N. S., Brickman, A. M., Andrews, H., Manly, J. J., Schupf, N., Lantigua, R., Wolock, C. J., Kamalakaran, S., Petrovski, S., Tosto, G., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.582 · Cited by 141 · cited 2×
“therefore haploinsufficiency of SORL1 appear, thus far, to only occur in in AD cases(Holstege et al., 2017; Raghavan et al., 2018).”
Ando, K., Brion, J.-P., Stygelbout, V., Suain, V., Authelet, M., Dedecker, R., Chanut, A., Lacor, P., Lavaur, J., Sazdovitch, V., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1111-z · Cited by 136
Bhalla, A., Vetanovetz, C. P., Morel, E., Chamoun, Z., Di Paolo, G., & Small, S. A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.030 · Cited by 130
Schwagerl, A. L., Mohan, P. S., Cataldo, A. M., Vonsattel, J. P., Kowall, N. W., & Nixon, R. A. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010443.x · Cited by 107
Sottejeau, Y., Bretteville, A., Cantrelle, F.-X., Malmanche, N., Demiaute, F., Mendes, T., Delay, C., Alves Dos Alves, H., Flaig, A., Davies, P., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0237-8 · Cited by 98 · cited 2×
“BIN1 expression correlates with Tau pathology(Holler et al., 2014) and BIN1 protein may interact directly with Tau, although this interaction may be disrupted by Tau phosphorylation(Sottejeau et al., 2015).”
BIN1 regulates BACE1 intracellular trafficking and amyloid-β production
Miyagawa, T., Ebinuma, I., Morohashi, Y., Hori, Y., Young Chang, M., Hattori, H., Maehara, T., Yokoshima, S., Fukuyama, T., Tsuji, S., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw146 · Cited by 95
Clathrin-independent endocytosis, retrograde trafficking, and cell polarity
Shafaq-Zadah, M., Dransart, E., & Johannes, L. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.05.009 · Cited by 76 · cited 1×
“Clathrin-independent pathways also exist (Mayor et al., 2014; Sandvig et al., 2018; Shafaq-Zadah et al., 2020) but will not be reviewed here.”
PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4
Narayan, P., Sienski, G., Bonner, J. M., Lin, Y.-T., Seo, J., Baru, V., Haque, A., Milo, B., Akay, L. A., Graziosi, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108224 · Cited by 75
Chai, Y. L., Chong, J. R., Weng, J., Howlett, D., Halsey, A., Lee, J. H., Attems, J., Aarsland, D., Francis, P. T., Chen, C. P., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12631 · Cited by 73 · cited 2×
“More recent work has suggested that Cat-D is upregulated in the AD neocortex and that Cat-D immunoreactivity was colocalized with neurofibrillary tangles(Chai et al., 2019).”
Kwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M., Fak, J., Olsen, O., Darnell, R. B., & Tessier-Lavigne, M. (2019) · Neuron · doi:10.1016/j.neuron.2019.11.010 · Cited by 70
The role of CD2AP in the Pathogenesis of Alzheimer's Disease
Tao, Q.-Q., Chen, Y.-C., & Wu, Z.-Y. (2019) · Aging and disease · doi:10.14336/ad.2018.1025 · Cited by 61 · cited 14×
“Furthermore, overexpression of CD2AP increased APP colocalization in late endosomes, stimulating APP degradation(Furusawa et al., 2019).”
InfluentialAndrew, R. J., De Rossi, P., Nguyen, P., Kowalski, H. R., Recupero, A. J., Guerbette, T., Krause, S. V., Rice, R. C., Laury-Kleintop, L., Wagner, S. L., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006379 · Cited by 55
Liao, F., Jiang, H., Srivatsan, S., Xiao, Q., Lefton, K. B., Yamada, K., Mahan, T. E., Lee, J.-M., Shaw, A. S., & Holtzman, D. M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0006-y · Cited by 53 · cited 1×
“Functionally, reduction of expression of CD2AP reduces Aβ peptides and lowers the Aβ42:40 ratio in neuroblastoma cell lines and transgenic mice(Liao et al., 2015).”
SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration
Huang, T. Y., Zhao, Y., Jiang, L.-L., Li, X., Liu, Y., Sun, Y., Piña-Crespo, J. C., Zhu, B., Masliah, E., Willnow, T. E., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171413 · Cited by 50 · cited 3×
“Interestingly, a more recent study showed that the AD-risk gene SORL1/SORLA interacts with the EphA4 receptor and attenuates Aβ-mediated EphA4 activation(Huang et al., 2017) thus impacting neurotoxicity and synaptic function.”
InfluentialA human brain vascular atlas reveals diverse cell mediators of Alzheimer’s disease risk
Yang, A. C., Vest, R. T., Kern, F., Lee, D. P., Maat, C. A., Losada, P. M., Chen, M. B., Agam, M., Schaum, N., Khoury, N., et al. (2021) · doi:10.1101/2021.04.26.441262 · Cited by 48
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Cited by
Wang, J., Fourriere, L., & Gleeson, P. A. (2024) · Biochemical Journal · doi:10.1042/bcj20240056 · Cited by 27
Jaye, S., Sandau, U. S., & Saugstad, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1378576 · Cited by 26
“Regulators of endosomal trafficking, which normally prevent BACE1 and APP from being delivered to the same compartment, have been identified as genetic risk factors for AD ( APOE4, PICALM, BIN1 ) (Szabo et al., 2022; Maninger et al., 2024).”
InfluentialSTING Deletion Protects Against Amyloid β‐induced Alzheimer's Disease Pathogenesis
Thanos, J. M., Campbell, O. C., Cowan, M. N., Bruch, K. R., Moore, K. A., Ennerfelt, H. E., Natale, N. R., Mangalmurti, A., Kerur, N., & Lukens, J. R. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70305 · Cited by 26
“60 Most notably, mutations in numerous endolysosomal genes have been identified as genetic risk factors for AD.”
Martá-Ariza, M., Leitner, D. F., Kanshin, E., Suazo, J., Giusti Pedrosa, A., Thierry, M., Lee, E. B., Devinsky, O., Drummond, E., Fortea, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02844-z · Cited by 15
Isoform- and cell-state-specific APOE homeostasis and function
Lindner, K., & Gavin, A.-C. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01470 · Cited by 13
“They are involved in recycling, transport, and degradation and seem to be impaired in AD from early stages (Szabo et al., 2022; Zhang et al., 2022b).”
Background
Metadata
- Authors
- Szabo, M. P., Mishra, S., Knupp, A., & Young, J. E.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 162
- Pages
- 105576
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W4200247264
- Cited by
- 82
- References
- 72
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.